15:15 - 16:45     ROOM N11

The Lancet


The Lancet/The Lancet Diabetes and Endocrinology - Research
Chairs: Markus Ketteler, Coburg, Germany
             Sarah Linklater, London, UK
Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial
Michel Azizi, Paris, France

Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised
controlled trial
F. Perry Wilson, New Haven, USA

Ceftolozane/tazobactam demonstrates superiority to levofloxacin in the treatment of complicated
urinary tract infections, including pyelonephritis: results from a randomised, doubleblind,
phase 3 trial (ASPECT-cUTI)
Obiamiwe Umeh, Lexington, USA

Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes:
a collaborative meta-analysis
Kunihiro Matsushita, Baltimore, USA

Worldwide access to treatment for end-stage kidney disease: a systematic review
Vlado Perkovic, Sydney, Australia

back to the timetable